Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease : Vasodilator capacity and cellular mechanisms

Inhaled nitric oxide (iNO) has been used to assess the vasodilator capacity of the pulmonary vascular bed in children with congenital heart disease and elevated pulmonary vascular resistance. Inhaled iloprost is a pulmonary vasodilator for the long-term treatment of pulmonary hypertension (PHT). Bec...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2001-01, Vol.103 (4), p.544-548
Main Authors: RIMENSBERGER, Peter C, SPAHR-SCHOPFER, Isabelle, BERNER, Michel, JAEGGI, Edgar, KALANGOS, Afksendiyos, FRIEDLI, Beat, BEGHETTI, Maurice
Format: Article
Language:English
Subjects:
Administration, Inhalation
Aerosols
Analysis of Variance
Biological and medical sciences
Cardiovascular system
Child
Child, Preschool
Cyclic AMP - blood
Cyclic GMP - blood
Heart Defects, Congenital - complications
Hemodynamics - drug effects
Humans
Hypertension, Pulmonary - drug therapy
Hypertension, Pulmonary - etiology
Hypertension, Pulmonary - physiopathology
Iloprost - administration & dosage
Infant
Lung - blood supply
Lung - drug effects
Lung - physiopathology
Medical sciences
Nitric Oxide - administration & dosage
Pharmacology. Drug treatments
Pulmonary Circulation - drug effects
Vascular Resistance - drug effects
Vasodilator Agents - administration & dosage
Vasodilator agents. Cerebral vasodilators
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhaled nitric oxide (iNO) has been used to assess the vasodilator capacity of the pulmonary vascular bed in children with congenital heart disease and elevated pulmonary vascular resistance. Inhaled iloprost is a pulmonary vasodilator for the long-term treatment of pulmonary hypertension (PHT). Because these 2 vasodilators act through different pathways (release of cGMP or cAMP, respectively), we compared the pulmonary vasodilator capacity of each. A total of 15 children with congenital heart disease and PHT who had elevated pulmonary vascular resistance (preoperative, n=10; immediately postoperative, n=5) were first given 20 ppm of iNO for 10 minutes; then, after baseline values were reached again, they were given aerosolized iloprost at 25 ng. kg(-1). min(-1) for another 10 minutes. Finally, iNO and iloprost were given simultaneously for 10 minutes. With iNO, the pulmonary vascular resistance and systemic vascular resistance ratio decreased from 0.48+/-0.38 to 0.27+/-0.16 (P:
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.103.4.544